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Abstract
Aims Hypoglycaemia presents a barrier to optimum diabetes management but data are limited on the frequency of
hypoglycaemia incidents outside of clinical trials. The present study investigated the rates of self-reported non-severe
hypoglycaemic events, hypoglycaemia awareness and physician discussion of events in people with Type 1 diabetes
mellitus or insulin-treated Type 2 diabetes mellitus.
Methods People in seven European countries aged >15 years with Type 1 diabetes or insulin–treated Type 2 diabetes
(basal-only, basal-bolus and other insulin regimens) were recruited via consumer panels, nurses, telephone recruitment
and family referrals. Respondents completed four online questionnaires. The first questionnaire collected background
information on demographics and hypoglycaemia-related behaviour, whilst all four questionnaires collected data on
non-severe hypoglycaemic events in the preceding 7 days.
Results Analysis was based on 11 440 respondent-weeks from 3827 respondents. All participants completed the first
questionnaire and 57% completed all four. The mean number of events/respondent–week was 1.8 (Type 1 diabetes) and
0.4–0.7 (Type 2 diabetes, with different insulin treatments) corresponding to annual event rates of 94 and 21–36,
respectively. A total of 63% of respondents with Type 1 diabetes and 49–64% of respondents with Type 2 diabetes,
treated with different insulin regimens, who experienced hypoglycaemic events, reported impaired hypoglycaemia
awareness or unawareness. A high proportion of respondents rarely or never informed their general practitioner/
specialist about hypoglycaemia: 65% (Type 1 diabetes) and 50–59% (Type 2 diabetes). Overall, 16% of respondents
with Type 1 diabetes and 26% of respondents with Type 2 diabetes reported not being asked about hypoglycaemia
during routine appointments.
Conclusion Non-severe hypoglycaemic events are common amongst people with Type 1 diabetes and insulin–treated
Type 2 diabetes in real-world settings. Many rarely or never inform their general practitioner/specialist about their
hypoglycaemia and the real burden of hypoglycaemia may be underestimated.
Diabet. Med. 31, 92–101 (2014)
Introduction
The goal of diabetes management for people with Type 1 or
Type 2 diabetes mellitus is to maintain normoglycaemia so
as to reduce diabetic complications and the risk of
mortality; however, the intensification of therapy to achieve
this goal may increase the incidence of hypoglycaemic
episodes.
Hypoglycaemia remains a common and unpredictable side
effect of insulin therapy, and has a negative physical and
emotional impact on people with diabetes [1]. Hypoglycae-
mic episodes are characterized as either severe or non-severe
according to whether assistance is required from another
individual, or whether the person with diabetes can manage
the event alone, respectively [2,3]. Non-severe hypoglycae-
mic events account for 88–98% of all hypoglycaemic events
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[4–6] and have been shown to affect functioning [7],
health-related quality of life [4,8], healthcare resource use
[4] and work productivity [7]. Furthermore, hypoglycaemia
presents a significant barrier to optimum diabetes manage-
ment, as fear of hypoglycaemic events may cause exaggerated
avoidance behaviour and consequently suboptimum insulin
therapy and poor glycaemic control [9,10]. Whilst the
importance of education about the recognition and treatment
of hypoglycaemia is acknowledged in the current European
Association for the Study of Diabetes and American Diabetes
Association consensus statement [11], the real-world levels of
communication between healthcare professionals and people
with diabetes regarding hypoglycaemia are not fully under-
stood.
Data on the frequency of hypoglycaemia, specifically
non-severe hypoglycaemic events, outside of clinical trial
settings are limited and varied [1,5,6,8]. The variability of
data is probably attributable to differing study populations
(degree of selection, Type 1 diabetes and/or insulin-treated
Type 2 diabetes), targets for glycaemic control, duration of
treatment, methods of data collection and country coverage
within these studies.
Our aim was to investigate the real-world frequency of
self-reported non-severe hypoglycaemic events, levels of
impaired hypoglycaemia awareness and discussion of hypo-
glycaemic events within physician consultations. We used a
multi-country questionnaire-based survey in a large non-
interventional cohort of people with Type 1 diabetes or
insulin-treated Type 2 diabetes. The questionnaire also
explored the health-related impact and economic burden of
hypoglycaemia, the results of which are to be provided in a
follow-on publication.
Subjects and methods
The questionnaire-based survey was conducted between
November 2011 and May 2012 and recruited respondents
from Austria, Denmark, Finland, Norway, Sweden, Switzer-
land and the Netherlands. Respondents were primarily
recruited via existing large consumer panels that were
established to reflect a representative sample of the general
diabetes population, based on age, gender and other demo-
graphic characteristics. Where sufficient numbers of respon-
dents could not be identified via consumer panels, other
methods of recruitment were initiated, including the use of
advertisements on diabetes-related websites and patient
association websites (with a link to the screener for inclusion
in the survey), face-to-face recruitment, telephone recruit-
ment and subsequent referrals from friends/family. In addi-
tion, some respondents were directly recruited at general
practitioner clinics by nurses who were asked to identify
participants and seek consent for participation, before
providing contact details for those eligible to take part in
the survey. All respondents completed a screening stage to
determine eligibility for study inclusion. Before study entry,
respondents were unaware that the survey related to hypo-
glycaemia. A target of 600 respondents per country was set
with an expectation that the probability of a hypoglycaemic
event would have a 95% CI of 4%.
The inclusion criteria were a diagnosis of either Type 1
diabetes or Type 2 diabetes from a healthcare professional,
current insulin treatment and age >15 years. In addition,
respondents were required to read and speak the native
language of the country in which they resided and have an
email address in order to complete the questionnaire online.
Respondents were offered a small incentive for completion of
the entire survey (€5–25), in line with current market
research guidelines and to ensure there was no undue
incentive to participate. All respondents were anonymous
according to the regulations and practice of the market
research governing bodies, the European Society for Opinion
and Marketing Research [12] and the European Pharmaceu-
tical Market Research Association [13].
Eligible respondents were invited by email to complete an
online questionnaire, in four waves. They received invita-
tions for the second, third and fourth questionnaires 7 days
after they had completed the previous questionnaire.
Questionnaires were adapted from those used in a previous
study [7], which had been designed using insights collected
during focus groups on the impact of hypoglycaemia
reported by people with diabetes [14]. Data collected in
the first questionnaire included respondent demographics,
previous experience with and awareness of hypoglycaemia,
the impact of hypoglycaemia and the number of non-severe
hypoglycaemic events and severe hypoglycaemic events.
What’s new?
• Limited data exist on the frequency of non-severe
hypoglycaemic events in people with Type 1 or Type 2
diabetes in real-world practice, as non-severe hypogly-
caemic events, by definition, do not require healthcare
professional interactions (are not routinely registered).
• The frequency of non-severe hypoglycaemic events in
real-world practice may differ from that observed in
clinical trials because of the characteristics of clinical
trial designs.
• To our knowledge, this is the first study reporting the
frequency of non-severe hypoglycaemic events in real--
world practice in the seven countries involved in our
study.
• Non-severe hypoglycaemic events are common amongst
people with Type 1 or insulin-treated Type 2 diabetes.
• Many people with diabetes rarely or never inform their
general practitioner/specialist about their hypoglyca-
emia and the real burden may be underestimated.
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Respondents were also asked about hypoglycaemia-related
discussions during general practitioner/specialist consulta-
tions. Respondents who had experienced a non-severe
hypoglycaemic event were asked whether they normally
informed their general practitioner/specialist after they had
had a hypoglycaemic event. A non-severe hypoglycaemic
event was defined as symptoms of hypoglycaemia (e.g.
sweating, shaking, headache) with or without a blood
glucose measurement, or a low blood glucose measurement
(≤3.1 mmol/L) without symptoms, that the individual
managed without assistance from another person. A severe
hypoglycaemic event was defined as an event of low blood
glucose level needing help from a third party to manage (e.g.
help from a family member or a healthcare professional,
including emergency room visits and hospitalization). Ques-
tions also referred to non-severe hypoglycaemic events
occurring during the daytime or the night-time (while the
respondent was in bed/asleep). The subsequent question-
naires focused only on the number of non-severe hypogly-
caemic events and the impact of these events. Completion of
the survey in four waves provided data for the number of
non-severe hypoglycaemic events occurring over the past
4 weeks, whilst minimizing the recall period (i.e. four 7-day
periods were reported). The estimated total amount of time
to complete all four questionnaires was 35 min. Question-
naires were completed anonymously but responses could be
tracked across the four waves by an identification number
assigned at study initiation.
Limits for upper and lower entry values were included
within the questionnaire to minimize erroneous values. In
addition, data were cleaned using a logical consistency check
that allowed the removal of individual answers for which
incorrect calculations had been made by a respondent (e.g.
where longer treatment duration than diabetes duration was
reported), or the removal of the respondent from the entire
analysis in instances where type of diabetes was not known or
where erroneous reporting of simple demographic variables
occurred (e.g. diabetes duration longer than current age).
The rate of non-severe hypoglycaemic events was calculated
using data from all respondents who completed at least one
wave of the survey. The first questionnaire collected data for
non-severe hypoglycaemic events in the last 4 weeks and the
last 7 days. All subsequent waves reported only the number of
non-severe hypoglycaemic events in the last 7 days, so the
estimated weekly rates from the 4-week rate provided in wave
one could be matched with the weekly rates reported by the
four times 7-day rates across waves one, two, three and four.
Annual event rates were calculated using the subsequent wave
mean event rate per respondent-week multiplied by 52.
The relationships between demographic factors and the
annual rate of non-severe hypoglycaemic events were
analysed in regression models. The continuous dependent
variable of the annual event rate was estimated by combining
two variables: the 4-weekly non-severe hypoglycaemia event
rate and, for respondents who did not experience a
hypoglycaemic event in the previous 4 weeks, answers to
the question, ‘How often do you normally have non-severe
hypoglycaemic events?’ This analysis used data collected
during the first wave of the survey. Analysis on Type 1 and
Type 2 diabetes was carried out separately. Regression
analyses were conducted for the whole study population, as
the study was not designed for cross-country comparisons.
The classification system for awareness of hypoglycaemia
was based on a prospectively validated study by Pedersen-
Bjergaard et al. 2003 [15]. Any respondent who answered
‘sometimes’ or ‘never’ to the question, ‘Can you feel when
your blood sugar is low?’ was classified as being unaware of
hypoglycaemia, those who answered ‘usually’ were classified
as having impaired awareness and those who answered
‘always’ were classified as aware.
Standard descriptive methods (means/percentage and stan-
dard deviations) were used to report results for respondents
in the following four groups: people with Type 1 diabetes,
people with Type 2 diabetes receiving basal-only/long-acting
insulin-only therapy, people with Type 2 diabetes receiving
basal-bolus/both short- and long-acting insulin therapy, or
people with Type 2 diabetes receiving another form of insulin
therapy. Comparisons were performed using t-tests and a
P value <0.05 was considered to indicate statistical
significance.
Results
A total of 3959 respondents across seven countries were
recruited to the study and 132 (3.3%) were excluded as a
result of inadequate questionnaire completion. The remaining
3827 respondents completed the initial survey, with 76, 66
and 57% completing waves two, three and four, respectively,
resulting in a total of 11 440 respondent-week records.
The demographics for respondents with Type 1 diabetes
and those with Type 2 diabetes are shown in Table 1 and
were similar across countries (data not shown). Differences
between respondents with Type 1 diabetes and respondents
with Type 2 diabetes were consistent with those expected
(age, diabetes duration etc.). Age and BMI were negatively
correlated with the annual rate of non–severe hypoglycaemic
events (P < 0.05). Female gender and duration of insulin
treatment were positively correlated with the annual event
rate (P < 0.05).
The mean self-reported non-severe hypoglycaemic event
rate was 1.8 per respondent-week for respondents with Type
1 diabetes and 0.5 for respondents with Type 2 diabetes
(Table 2). Individual country data are also reported in
Table 2. Rates for respondents with Type 2 diabetes were 0.4
(respondents receiving basal-only/long-acting insulin-only
therapy), 0.7 (respondents receiving basal-bolus/both short-
and long-acting insulin therapy) and 0.5 (respondents
receiving another form of insulin therapy; Table 2). The
calculated mean annual event rates were therefore 91.0,
20.3, 35.4 and 27.0 in the four groups (Table 2). The
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proportion of nocturnal non-severe hypoglycaemic events
were slightly greater in respondents with Type 2 diabetes
than in respondents with Type 1 diabetes: 22% (Type 1
diabetes), 32% (respondents with Type 2 diabetes receiving
basal-only/long-acting insulin-only therapy), 22% (respon-
dents with Type 2 diabetes receiving basal-bolus/both short-
and long-acting insulin therapy) and 27% (respondents with
Type 2 diabetes receiving another form of insulin therapy;
Table 2). Four-week non-severe hypoglycaemic event rates
recalled by respondents in questionnaire one were similar to,
although slightly lower than, those collected over the four
waves of the study (Table 2).
The mean number of self-reported severe hypoglycaemic
events experienced in the last year was 0.7 for respondents
with Type 1 diabetes, 0.1 for respondents with Type 2
diabetes receiving basal-only/long-acting insulin-only ther-
apy, 0.2 for respondents with Type 2 diabetes receiving
basal-bolus /both short- and long-acting insulin therapy and
0.2 for respondents with Type 2 diabetes receiving another
form of insulin therapy (Table 2).
Overall, 76% of study respondents (87% of respondents
with Type 1 and 59–78% of respondents with Type 2
diabetes) had previously experienced a hypoglycaemic event
at any point (i.e. not just in the study recall period). In
respondents who had previous experience of hypoglycaemic
events, impaired awareness was reported by 53% of respon-
dents with Type 1 diabetes, 45% of respondents with Type 2
diabetes receiving basal-only/long-acting insulin therapy
only, 43% of respondents with Type 2 diabetes receiving
basal-bolus/both short- and long-acting insulin therapy and
43% of respondents with Type 2 diabetes receiving another
form of insulin therapy (Table 3). A further 10, 19, 6 and
8% were classified as unaware for each respondent type,
respectively. Respondents with Type 1 diabetes who were
unaware had significantly higher rates of non-severe hypo-
glycaemic events than those who were always aware
(P < 0.05; Table 3). Among respondents with Type 2
diabetes receiving basal-only/long-acting insulin-only ther-
apy and respondents with Type 2 diabetes receiving
basal-bolus/both short- and long-acting insulin therapy,
respondents with impaired awareness had significantly
higher non-severe hypoglycaemic event rates than those
who were aware (P < 0.05). In respondents with Type 2
diabetes receiving another form of insulin therapy, signif-
icantly lower non-severe hypoglycaemic event rates were
observed in unaware respondents than in respondents who
were always aware (P < 0.05; Table 3). Significantly higher
rates of severe hypoglycaemic events were reported by
respondents with Type 1 diabetes classified either as unaware
or as having impaired awareness, compared with aware
respondents (P < 0.05).
A high proportion of respondents who had experienced a
non-severe hypoglycaemic event stated that they ‘rarely’
or ‘never’ informed their general practitioner/specialist
about their hypoglycaemia: 65% (respondents with Type 1
Table 1 Respondent-related characteristics
Type 1
diabetes
Type 2
diabetes
Number of respondents,
n (%)
1631 (43) 2196 (57)
Mean (SD) age* 44.3 (14.1) 60.3 (10.7)
Gender, female, n(%)† 722 (44) 735 (33)
Education, n (%)‡
Primary school 244 (15) 393 (18)
High school 808 (49) 1147 (52)
University (plus PhD.
or higher)
517 (32) 558 (25)
Other 62 (4) 98 (5)
Mean (SD) BMI* 25.87 (4.88) 31.54 (6.39)
Smoking, n (%)§
Smoker 458 (28) 450 (20)
Ex-smoker 418 (26) 1008 (46)
Non-smoker 755 (46) 738 (34)
Diabetes duration, n (%)
<2 years 20 (1) 41 (2)
2–5 years 220 (14) 317 (15)
5–9 years 145 (10) 394 (19)
10–14 years 197 (13) 546 (26)
15 + years 957 (62) 806 (38)
Insulin treatment type,
n (%)¶
Long-acting insulin only 134 (8) 812 (37)
Both short- and
long-acting insulin
1058 (65) 942 (43)
Other insulin types 439 (27) 442 (20)
Duration of insulin
treatment, n (%)**
<2 years 113 (7) 311 (14)
2–5 years 189 (12) 741 (35)
5–9 years 136 (9) 394 (18)
10 + years 1101 (72) 659 (32)
HbA1c
§
Mean mmol/mol (SD); 61 (16.1) 60 (16.9)
National Glycohaemoglobin
Standardisation
Programme%, (SD)
7.7 (1.5) 7.6 (1.5)
Medical complications,
none reported, n (%)††
1036 (64) 1148 (52)
*Significant negative correlation with yearly number of
non-severe hypoglycaemic events (for both Type 1 diabetes
and Type 2 diabetes, according to regression analysis;
P < 0.05).
†Significant positive correlation with yearly number of non-
severe hypoglycaemic events (for both Type 1 diabetes and
Type 2 diabetes, according to regression analysis; P < 0.05).
‡Significant (P < 0.05) negative correlation with yearly number
of non-severe hypoglycaemic events (Type 2 diabetes only).
§No significant correlation with yearly number of non-severe
hypoglycaemic events.
¶Variable not included in the regression analysis.
**Duration of insulin treatment was correlated with diabetes
duration, and thus duration of treatment was included in the
regression analysis. A significant positive correlation was found
between duration of treatment and yearly number of non-severe
hypoglycaemic events (for both Type 1 diabetes and Type 2
diabetes; P < 0.05).
††Medical complications were correlated with age. Medical
complications were not significantly associated with yearly
number of non-severe hypoglycaemic events, independent of
their association with age. Questionnaire options for medical
complications included: None, Eye problems, Neuropathy,
Cardiovascular disease, Renal disease, Amputations, Other
(please specify).
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diabetes), 50% (respondents with Type 2 diabetes receiving
basal-only/long-acting insulin-only therapy), 59% (respon-
dents with Type 2 diabetes receiving basal-bolus/both short-
and long-acting insulin therapy) and 53% (respondents with
Type 2 diabetes receiving another form of insulin therapy;
Table 4). The lowest level of communication was reported in
the Netherlands (data not shown). The proportion of
respondents in the Netherlands who rarely or never informed
their general practitioner/specialist about their hypoglycae-
mic events was 86% (respondents with Type 1 diabetes),
64% (respondents with Type 2 diabetes receiving basal-only
therapy/long-acting insulin-only therapy), 77% (respondents
with Type 2 diabetes receiving basal-bolus/both short- and
long-acting insulin therapy) and 79% (respondents with
Type 2 diabetes receiving another form of insulin therapy).
Event rates for non-severe hypoglycaemic events were
significantly higher for respondents with Type 1 diabetes or
Type 2 diabetes who rarely or never informed a physician
about their non-severe hypoglycaemic events (P < 0.05).
When respondents were asked about topics discussed during
general practitioner/specialist consultations, 17% (Type 1
diabetes), 28% (Type 2 diabetes receiving basal-only/
long-acting insulin-only therapy), 26% (Type 2 diabetes
receiving basal-bolus/both short- and long-acting insulin
therapy) and 21% (Type 2 diabetes receiving another form of
insulin therapy) of respondents stated that their general
Table 3 Self-reported respondent awareness of hypoglycaemia and corresponding event rates in respondents who had previously experienced a
hypoglycaemic event
Respondents, N = 2925*
Type 1
diabetes,
n = 1420
Type 2 diabetes
BOT, n = 479 BB, n = 736 Other, n = 290
Can you feel when your blood sugar is low? Always aware,% 36 36 51 49
Impaired awareness,% 53 45 43 43
Unaware,% 10 19 6 8
Mean (SD) NSHE rates of those respondents
who are aware, have impaired
awareness or are unaware
Always aware 1.7 (2.3) 0.5 (1.0) 0.8 (1.5) 0.7 (1.4)
Impaired awareness 1.9 (2.2) 0.6 (1.2)† 0.9 (1.5)† 0.7 (1.2)
Unaware 2.6 (3.0)† 0.4 (1.0) 0.7 (1.1) 0.3 (0.7)†
Mean (SD) SHE rates of those respondents who
are aware, have impaired awareness or are
unaware
Always aware 0.4 (1.8) 0.2 (0.6) 0.2 (0.9) 0.2 (0.5)
Impaired awareness 0.8 (1.9)† 0.2 (1.1) 0.2 (0.7) 0.2 (1.2)
Unaware 2.7 (5.2)† 0.1 (0.5) 0.4 (1.0) 0.2 (0.5)
BOT, basal-only/long-acting insulin-only therapy; BB, basal-bolus/short- and long-acting insulin therapy; Other, e.g. mixed insulin; NSHE,
non-severe hypoglycaemic event; SHE,severe hypoglycaemic event.
*All respondents who had previously experienced a NSHE at any point (i.e. not just in the study recall period; n = 2925).
†P < 0.05 significance against always aware.
Table 4 Communication between respondents and general practitioners/specialists
All respondents, N = 3827*
Type 1 diabetes,
n = 1631
Type 2 diabetes
BOT, n = 812 BB, n = 942 Other, n = 442
General practitioner/specialist did not ask
about hypoglycaemia during routine
appointments,%*
17 28 26 21
All respondents who have ever
experienced a NSHE, N = 2925†
Type 1 diabetes,
n = 1420
Type 2 diabetes
BOT, n = 479 BB, n = 736 Other, n = 290
Proportion of respondents rarely or never
informing their general practitioner/specialist
of a hypoglycaemic event, %†
65 50 59 53
Mean (SD) NSHE rates of those respondents
communicating versus those who do not tell
their general practitioner/specialist†
Always/Mostly 1.5 (1.9) 0.4 (0.9) 0.6 (1.0) 0.6 (0.9)
Rarely/Never 2.2 (2.3)‡ 0.6 (1.0)‡ 1.0 (1.5)‡ 0.8 (1.2)
BOT, basal-only/long-acting insulin-only therapy; BB, basal-bolus/short- and long-acting insulin therapy; Other, e.g. mixed insulin; NSHE,
non-severe hypoglycaemic event.
*All respondents completing questionnaire one (n = 3827).
†All respondents who have ever experienced a NSHE (n = 2925).
‡P < 0.05 significance.
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practitioner/specialist ‘did not ask about hypoglycaemia
during routine appointments’ (Table 4).
Discussion and conclusions
This study captures the self-reported, recalled rates of
non-severe hypoglycaemic events and severe hypoglycaemic
events in both people with Type 1 diabetes and those with
insulin-treated Type 2 diabetes, and shows that hypoglycae-
mic events remain a common adverse event of insulin therapy
in both groups. The majority of the published literature on
hypoglycaemic event rates includes only people with Type 1
diabetes, or is focused on reporting severe hypoglycaemic
events only, and may not adequately reflect the frequency of
hypoglycaemic events (especially non-severe hypoglycaemic
events) across the insulin-treated diabetes population. In
contrast, the present study explored the frequency of
non-severe hypoglycaemic events and severe hypoglycaemic
events in people with Type 1 diabetes and people with
insulin-treated Type 2 diabetes across seven European
countries.
The recalled rates of non-severe hypoglycaemic events for
respondents with Type 1 diabetes (1.8 per respondent, per
week) in this study are comparable with results from three
previously conducted studies in Northern Europe, which
reported non-severe hypoglycaemic event rates of 1.8, 2.0 and
2.2 per respondent, per week [6,16,17]. Rates of non-severe
hypoglycaemic events for respondents with Type 2 diabetes in
the current study are higher than those reported in a
prospective single-centre study in Scotland, UK (0.4–0.7 vs
0.3 per respondent, per week) but this variation may be
attributable to differences in the geographical region, Type 2
diabetes treatment regimen, and study sample size, or the way
in which hypoglycaemic events had been defined [5]. Hypo-
glycaemic events occurred less frequently in respondents with
insulin-treated Type 2 diabetes compared with respondents
with Type 1 diabetes, and previous studies suggest the
frequency of severe hypoglycaemic events in Type 2 diabetes
to be approximately one-third of that experienced by people
with Type 1 diabetes [5,18]. The results reported in the
present study for severe hypoglycaemic events are consistent
with this trend (Type 1 diabetes 0.7; Type 2 0.1–0.2) and
suggest a similar ratio for non-severe hypoglycaemic events
(Type 1 diabetes 1.8; Type 2 0.4–0.7). It should be noted that
the frequency of hypoglycaemic events in respondents with
Type 2 diabetes varies according to the treatment regimen
(basal-only/long-acting insulin-only therapy, basal-bolus/
both short- and long-acting insulin therapy, or another form
of insulin therapy); however, this was to be expected given the
different insulin coverage they provide [11].
Overall, nocturnal events represented between one quarter
and one third of all non-severe hypoglycaemic events. In
the present study, the proportion of overall non-severe
hypoglycaemic events occurring at night was 22% (respon-
dents with Type 1 diabetes), 32% (respondents with Type 2
diabetes receiving basal-only/long–acting insulin-only ther-
apy), 22% (respondents with Type 2 diabetes receiving
basal-bolus/both short- and long-acting insulin therapy), and
27% (respondents with Type 2 diabetes receiving another
form of insulin therapy). Few other studies have reported rates
of nocturnal events, although the proportion of nocturnal
events would be expected to vary between insulin regimens.
In the present study, we investigated levels of hypoglyca-
emia awareness and reported 10% (Type 1 diabetes) and
6–19% (Type 2 diabetes) of respondents to be classified as
unaware and 53% (Type 1 diabetes) and 43–45% (Type 2
diabetes) to have impaired awareness of hypoglycaemia
(based on respondents with experience of hypoglycaemic
events). A comparable proportion of respondents with Type
1 diabetes were found to have impaired awareness (47%) or
be classified as unaware (13%) in a 1-year prospective study
that used the validated question, ‘Do you recognise symp-
toms when you have a hypo?’ [15]. Furthermore, a cross-
sectional study in a cohort of 401 people with Type 2
diabetes, also using this question, reported a similar propor-
tion of respondents with impaired awareness (46%) to that
in the current study (43–45%) [18]. There is no consensus on
how to classify awareness, but our method benefits from the
use of three categories (instead of two, ‘aware’ or ‘unaware’,
as in the Clarke et al. [19] and Gold et al. [20] methods),
which enables identification of the gradual loss of awareness.
In addition, it is the only method proven to perform similarly
across language barriers [21].
Some consideration should be given to the different
respondent demographics within the current study. For
example, symptoms of hypoglycaemia have been shown to
decline with increasing age and the prevalence of impaired
awareness of hypoglycaemia is reported to increase with
duration of Type 1 diabetes [6]; results may be confounded
by these factors. In addition, the study by Akram et al. [18]
reported impaired awareness of hypoglycaemia to be the
most important risk factor for severe hypoglycaemia. Results
of the current study show that respondents with Type 1
diabetes classified as unaware or as having impaired aware-
ness of hypoglycaemia reported significantly higher rates
(P < 0.05) of severe hypoglycaemic events than respondents
who were always aware. Unaware respondents with Type 1
diabetes also reported significantly higher rates of non-severe
hypoglycaemic events compared with aware respondents
(P < 0.05). This could be explained by unaware respondents
failing to take action to prevent the onset of an event because
of an inability to recognize the symptoms of low blood sugar.
Additionally, this inability may cause respondents to over-
compensate by testing their blood glucose more frequently,
resulting in the identification of more events; however, this is
an area that requires further investigation, especially as these
trends were not observed in respondents with Type 2
diabetes.
An important finding of the current study was the high
proportion of respondents with Type 1 diabetes (65%) and
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Type 2 diabetes (50–59%) who rarely or never informed
their general practitioner/specialist about their hypoglycae-
mic events. Despite these results, only 17% of respondents
with Type 1 diabetes and 21–28% of respondents with Type
2 diabetes said that their general practitioner/specialist did
not ask them about hypoglycaemia during routine appoint-
ments, suggesting some level of communication regarding
hypoglycaemic events is taking place. The reluctance of
people with diabetes to discuss their hypoglycaemia may be
caused by wider factors such as concerns regarding driving
privileges [9], implications for employment, or fear that they
may be perceived by their general practitioner/specialist to
have poor control of their diabetes. Further research is
needed to understand the reasoning behind why people may
not actively be reporting their hypoglycaemic events. Along
with discussions on the frequency of non-severe hypoglycae-
mic events and severe hypoglycaemic events, other important
aspects such as impaired hypoglycaemia awareness [18] and
fear of hypoglycaemia [9,10] should be addressed, given that
these are associated with an increased risk of severe
hypoglycaemic events [18] and a risk of suboptimum
glycaemic control [9,10], respectively. An opportunity exists
for more standardized measures of these self-reported out-
comes, which may also help to improve understanding for
people with diabetes, and improve communication levels.
With the endorsement by both the American Diabetes
Association and the European Association for the Study of
Diabetes of education regarding recognition and treatment of
hypoglycaemia [11], it is hoped that communication between
people with diabetes and their physicians will increase
further. Whilst greater education could be expected to
improve blood glucose management, there will still be an
underlying increase in hypoglycaemic complications as insu-
lin treatment regimens are intensified over time [1]. This is
supported by our current regression analysis, where the
number of non-severe events increased with duration of
insulin treatment.
The frequency of hypoglycaemic events reported during
randomized trials, such as the Diabetes Control and Com-
plications Trial [22], and the United Kingdom Prospective
Diabetes Study [23], may not be reflective of the incidence in
real-world practice because of trial inclusion and exclusion
criteria and because observational studies have reported a
higher incidence of hypoglycaemic events in unselected
populations [1]. In addition, there are key benefits to
obtaining data directly from people with diabetes, particu-
larly since a high number of them are not reporting
non-severe hypoglycaemic events to their doctor.
It is important that the limitations of this study are
considered. Respondent demographics show that 8% of
respondents with Type 1 diabetes receive long-acting
insulin-only therapy. It is likely that this figure may be
the result of incorrect reporting of diabetes type by
respondents with Type 2 diabetes. As a result, given that
respondents with Type 2 diabetes have fewer hypoglycae-
mic events, our study may underestimate the frequency of
events for respondents with Type 1 diabetes. The survey is
based upon the recall of both severe hypoglycaemic events
and non-severe hypoglycaemic events and the interpretation
of symptoms is open to bias. A previous study showed that
a respondent’s ability to remember non-severe hypoglycae-
mic events during the previous week was not significantly
different from the prospective recording of events over
1 week [6]. The current study was therefore designed to
maximize the optimum recall period, by asking respondents
to record events occurring in the previous week for each of
the four questionnaires over 4 consecutive weeks. Also, a
previous study has shown that people with Type 1 diabetes
and people with Type 2 diabetes are able to accurately
recall severe hypoglycaemic events within a 1-year period
(corresponding to the recall period in the current study)
[15]. There is also the potential that the duration of the
study may over- or underestimate the annual frequency of
hypoglycaemia, given that seasonal variation was not
considered (the study was conducted December–May).
The recruitment of respondents, mostly via online panels
and the requirement of an email address in order to
participate in the study could have introduced selection
bias; however, the internet penetration rates for all of the
countries studied are high (80–97%) [24]. The anonymous
nature of the online panel may allow a better means of
obtaining self-reported data on areas such as communica-
tion levels with physicians. Recruitment was via broad
panels reflective of the general population and respondents
were invited via email to participate in the survey by
following a link, and were not informed that the survey was
about hypoglycaemia before they clicked on the link to
enter the survey. There are therefore no reasons to suggest
any selection bias towards people struggling with hypo-
glycaemia in the first wave of the study; however, since the
response rates for subsequent waves diminished (76, 66 and
57% of respondents completed waves two, three and four,
respectively) we cannot exclude the possibility that later
waves were completed by respondents who had more
experience of hypoglycaemic events. Nevertheless, a sub-
sequent analysis comparing event rates for the different
waves did not suggest any trends towards higher frequency
in later waves. The target recruitment rate of 600 respon-
dents per country was not reached in Austria, Norway and
Switzerland because of difficulties in accessing people with
diabetes; however, results were remarkably consistent
across the countries. Some respondents did not complete
all four waves, but only small changes in the non-severe
hypoglycaemic event rates (1.09 in wave 1 to 0.93 in
wave 4) were seen when comparing data across waves.
This was a descriptive study, therefore, few comparisons
were explored and no adjustments were made for
multiple cross-country comparisons; however, variations in
non-severe hypoglycaemic event rates across countries were
1.3–2.0 per respondent, per week in Type 1 diabetes, and
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0.2–1.0 per respondent, per week in Type 2 diabetes
(0.2–0.5 in Type 2 diabetes respondents receiving basa-
l-only/long-acting insulin-only therapy, 0.5–1.0 in Type 2
diabetes respondents receiving basal-bolus/both short- and
long-acting insulin therapy and 0.2–0.9 in Type 2 diabetes
respondents receiving another form of insulin therapy). This
might reflect other demographic differences which were not
captured, such as local differences in treatment regimens,
different patient education levels or targets for glycaemic
control. Additionally, the recruitment method does not
differentiate between primary and secondary care patients,
which may also have an impact.
Despite these limitations, the present study reports the
real-world rates of hypoglycaemic events in a large number
of people with Type 1 diabetes and people with Type 2
diabetes across seven European countries and provides
evidence for a need to minimize the frequency of hypo-
glycaemia. It is acknowledged that both severe and
non-severe hypoglycaemic events are more frequent in
people with Type 1 diabetes, but the associated social and
economic burden of events in people with Type 2 diabetes
is likely to be substantial given the global epidemic of Type
2 diabetes [25]. Hypoglycaemia presents a barrier to
optimum glycaemic control, increasing the risk of diabetic
complications and mortality; therefore, discussion during
physician consultations and education on the recognition
and treatment of hypoglycaemic events for people with
diabetes are imperative to encourage greater communica-
tion with physicians.
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